Pfizer Inc. $PFE Shares Sold by Heritage Investors Management Corp

Heritage Investors Management Corp trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 13.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 402,987 shares of the biopharmaceutical company’s stock after selling 62,159 shares during the quarter. Heritage Investors Management Corp’s holdings in Pfizer were worth $10,268,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in PFE. Brighton Jones LLC increased its holdings in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. Checchi Capital Advisers LLC grew its holdings in shares of Pfizer by 3.4% in the 2nd quarter. Checchi Capital Advisers LLC now owns 35,224 shares of the biopharmaceutical company’s stock worth $854,000 after acquiring an additional 1,159 shares during the last quarter. Wealthcare Advisory Partners LLC raised its position in shares of Pfizer by 21.5% during the second quarter. Wealthcare Advisory Partners LLC now owns 154,736 shares of the biopharmaceutical company’s stock worth $3,751,000 after purchasing an additional 27,341 shares during the period. Finally, MBL Wealth LLC lifted its holdings in shares of Pfizer by 24.4% during the second quarter. MBL Wealth LLC now owns 15,764 shares of the biopharmaceutical company’s stock valued at $382,000 after purchasing an additional 3,094 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.9%

Pfizer stock opened at $26.68 on Tuesday. The company’s fifty day simple moving average is $25.54 and its 200-day simple moving average is $25.05. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The stock has a market cap of $151.67 billion, a P/E ratio of 15.51 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. Pfizer’s payout ratio is 100.00%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target to $27, citing a shifting focus on obesity data that could re-rate Pfizer if pipeline results improve. Cantor Fitzgerald Raises PT to $27
• Positive Sentiment: UK industry self-regulator found Sanofi breached rules with unsubstantiated claims about its RSV therapy versus Pfizer’s vaccine — a reputational win that supports Pfizer’s vaccine positioning. Sanofi Breach Over RSV Claims
• Positive Sentiment: Management is reshaping the portfolio toward obesity, vaccines and pricing changes; investors see this as a potential multi-year growth pivot and yield support (Pfizer is highlighted for income investors). Pfizer Reshapes Portfolio With Obesity Bet
• Neutral Sentiment: Q4 earnings are due Feb. 3 before the open; previews focus attention on pipeline commentary (especially obesity/GLP-1 positioning) and guidance — the release, not yet reflected in results, is the main near-term catalyst. Is Pfizer a Good Stock to Buy before Earnings?
• Negative Sentiment: Several outlets and analyst models expect lower Q4 earnings and some firms have trimmed forecasts ahead of the call — downside surprise to EPS or guidance could pressure the stock. Pfizer Likely To Report Lower Q4 Earnings
• Negative Sentiment: Ongoing structural headwinds — patent expiries on blockbusters, intense GLP‑1 competition and pricing pressure — remain material risks that could limit upside absent strong pipeline news. 3 Headwinds Facing Pfizer in 2026

Analyst Ratings Changes

PFE has been the topic of several recent analyst reports. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a report on Wednesday, November 5th. TD Cowen restated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Morgan Stanley reduced their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Finally, Cantor Fitzgerald increased their target price on Pfizer from $24.00 to $27.00 and gave the company a “neutral” rating in a report on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $28.06.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.